Trial Profile
A large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Sep 2020
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CONFIRM
- Sponsors Novo Nordisk
- 05 Oct 2018 Results comparing the real-world effectiveness of insulin degludec (degludec) and insulin glargine 300 units/mL (glargine U300) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 29 Jun 2018 New trial record
- 26 Jun 2018 Primary endpoint has been met. (Change in HbA1c of adult patients treated with Tresiba compared to those treated with insulin glargine U300. ( baseline to six months follow-up.)) as per results presented at the 78th Annual Scientific Sessions of the American Diabetes Association